B PURUI - Trademark Details
Status: 709 - Registration cancelled because registrant did not file an acceptable declaration under Section 71
Image for trademark with serial number 79143546
Serial Number
79143546
Registration Number
4634904
Word Mark
B PURUI
Status
709 - Registration cancelled because registrant did not file an acceptable declaration under Section 71
Status Date
2021-05-28
Filing Date
2013-11-28
Registration Number
4634904
Registration Date
2014-11-11
Mark Drawing
3000 - Illustration: Drawing or design which also includes word(s)/ letter(s)/number(s) Typeset
Design Searches
261712 - Chevrons and angles.
Published for Opposition Date
2014-08-26
Attorney Name
John Alumit
Law Office Assigned Location Code
L10
Employee Name
CLARK, ROBERT C
Statements
Indication of Colors claimed
Color is not claimed as a feature of the mark.
Description of Mark
The mark consists of the name "PURUI" located beneath the letter "b" inside a geometric design above a chevron.
Goods and Services
Pharmaceutical preparations in injection, tablet, and liquid for treating allergic rhinitis and asthma, diabetes, skin disorders, allergies, hypertension; Chinese Medicine in the nature of medicinal herbs; Medicinal alcohol; Pesticides; Hormones, namely, Eplerenone for treating hypertension; Fluticasone Propionate for preventing and treating allergic rhinitis; topical corticosteroid preparations, namely, diflucortolone for topical corticosteroids anti-inflammatory; Deflazacort for treating adrenal cortical hypofunction, autoimmune disease, allergic diseases and diseases of the blood system, Betamethasone for treating allergic and autoimmune inflammatory diseases, active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, severe dermatitis, and acute leukemia; Dexamethasone for treating autoimmune diseases, allergy, inflammation, asthma and ophthalmology disease; Dexamethasone for treating Inflammatory and allergic diseases; Dexamethasone sodium phosphate for treating fever, 6-methyl prednisolone for treating inflammation; steroid hormones, namely, cortisol for treating adrenal insufficiency, arthritis pauperum, rheumatic fever, arthrolithiasis, bronchial asthma, allergic dermatitis, seborrheic dermatitis, pruritus, iridocyclitis, conjunctivitis, keratitis, scleritis, tuberculous meningitis, arthritis, pleurisy, tenosynovitis, acute and chronic sprain, and tendon strain; Hydrocortisone Acetate for treating rheumatic arthritis, acute articular rheumatism, arthrolithiasis, bronchial asthma, tuberculous, purulent meningitis, tuberculous pleurisy, pyothorax, arthritis, peritendinitis, sprain, hyde's disease, and lichen planus; Medroxyprogesterone Acetate for treating algomenorrhea, functional amenorrhea, dysfunctional uterine bleeding, threatened abortion and habitual abortion, endometriosis uterine, mammary cancer, adenocarcinoma of endometrium, and renal carcinoma; Cyproterone Acetate for treating prostatic carcinoma, hirsutism, and androgenetic alopecia; Prednisolone for treating allergic and inflammatory diseases; Prednisolone Acetate for treating dermatitis, eczema, lichen planus circumscriptus, seborrheic dermatitis, rheumatism, arthritis deformans, Biett's disease, bronchial asthma, dropsical nephritis, essential thrombopenia, granulocytopenia, acute lymphatic leukemia, adrenal insufficiency, and dermatitis exfoliativa; Astenile for treating advanced cervix mature insufficiency; Trenbolone Acetate for treating chronic wasting disease, ill and frail thin, frail after operation, osteoporosis, children dysplasia, and aplastic anemia; Stanazolol for treating hereditary angioneurotic edema, and cacotrophy; Oxymetholone for treating chronic wasting disease, infirm, sick and postoperative weak thin, nausea, edema, liver dysfunction and jaundice; Estradiol for treating estrogen deficiency, metastatic breast cancer, advanced prostate cancer, acne, aleucocytosis, and postcoital contraception; Estriol for treating cervicitis, auxiliary medicine and abortion of midtrimester induction of labor, prostatauxe, prostatic carcinoma, aleucocytosis, and haemorrhage
Name/Portrait Description and/or Consent Statement
The name(s), portrait(s), and/or signature(s) shown in the mark does not identify a particular living individual.
Translation of Words in Mark
The wording "PURUI" has no meaning in a foreign language.
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
F - Section 71 - Cancelled
Class Status Date
2021-05-28
Primary Code
005
Correspondences
Name
John Alumit
Address
Please log in with your Justia account to see this address.
International Registrations
International Registration Number
1194419
International Registration Date
2013-11-28
International Publication Date
2014-03-06
International Renewal Date
2023-11-28
Auto Protection Date
2015-09-06
International Status
001 - Request for extension of protection established
International Status Date
2014-03-06
Priority Claimed In
False
First Refusal In
True
Trademark Events
Event DateEvent Description
2014-03-06SN ASSIGNED FOR SECT 66A APPL FROM IB
2014-03-08NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
2014-03-12APPLICATION FILING RECEIPT MAILED
2014-03-13ASSIGNED TO EXAMINER
2014-03-13NON-FINAL ACTION WRITTEN
2014-03-14NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
2014-03-14REFUSAL PROCESSED BY MPU
2014-03-14NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
2014-04-04REFUSAL PROCESSED BY IB
2014-06-06TEAS RESPONSE TO OFFICE ACTION RECEIVED
2014-06-16ASSIGNED TO LIE
2014-06-27CORRESPONDENCE RECEIVED IN LAW OFFICE
2014-06-27TEAS/EMAIL CORRESPONDENCE ENTERED
2014-07-11FINAL REFUSAL WRITTEN
2014-07-11FINAL REFUSAL E-MAILED
2014-07-11NOTIFICATION OF FINAL REFUSAL EMAILED
2014-07-15TEAS REQUEST FOR RECONSIDERATION RECEIVED
2014-07-15CORRESPONDENCE RECEIVED IN LAW OFFICE
2014-07-16TEAS/EMAIL CORRESPONDENCE ENTERED
2014-07-17APPROVED FOR PUB - PRINCIPAL REGISTER
2014-07-23LAW OFFICE PUBLICATION REVIEW COMPLETED
2014-08-06NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
2014-08-06NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
2014-08-06NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
2014-08-22NOTIFICATION PROCESSED BY IB
2014-08-26PUBLISHED FOR OPPOSITION
2014-08-26OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
2014-11-11REGISTERED-PRINCIPAL REGISTER
2015-02-11FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
2015-04-06FINAL DISPOSITION PROCESSED
2015-04-06FINAL DISPOSITION NOTICE SENT TO IB
2015-04-24FINAL DECISION TRANSACTION PROCESSED BY IB
2016-11-17CHANGE OF NAME/ADDRESS REC'D FROM IB
2019-11-11COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
2021-05-28CANCELLED SECTION 71
2022-01-28TOTAL INVALIDATION OF REG EXT PROTECTION CREATED